Katy de Valle
Katy de Valle
Contact
Email
show email address
Top Publications
- Dijkstra, JN, Erasmus, CE, Laurian, P, Roets, A, Dodd, M, Irving, K, Moreno, CAM, Woodcock, IR, Voermans, NC, Willis, T, et al. Framing childhood-onset facioscapulohumeral dystrophy: from first symptoms to future trials.. Neuromuscul Disord 62: 106385 2026 view publication
- Woodcock, I, Tachas, G, Desem, N, Houweling, P, Yiu, E, Kean, M, Emmanuel, J, Kennedy, R, Carroll, K, de Valle, K, et al. A Phase 2 open-label study to determine the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy. 2026 view publication
- Dijkstra, JN, Henzi, BC, Mathews, KD, Erasmus, CE, Knox, R, Willis, T, de Valle, K, ENMC 279th Workshop Study Group. 279th ENMC international workshop: Classification, clinical care, outcome measures and biomarkers in childhood onset facioscapulohumeral dystrophy: towards standardizing clinical care and ensuring clinical trial readiness. Hoofddorp, The Netherlands, 1-3 November 2024.. Neuromuscul Disord 55: 106236 2025 view publication
- Coles, CA, Jalali, S, de Valle, K, Manton, N, Karlaftis, V, Attard, C, Galea, E, Forbes, R, Piers, AT, Clark, DR, et al. Detailed immune cell profiling of paediatric patient with limb girdle muscular dystrophy R3.. J Neurol Sci 476: 123629 2025 view publication
- Woodcock, IR, de Valle, K, Cairns, A, Davidson, ZE, Kean, M, Varma, N, Grobler, A, Metz, D, Carroll, K, Dilek, N, et al. Effect of creatine monohydrate on motor function in children with facioscapulohumeral muscular dystrophy: A multicenter, randomized, double-blind placebo-controlled crossover trial.. Pharmacotherapy 45(6) : 341 -351 2025 view publication
Page 1 of 8
Career information
Share //
